Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a $491.00 price target by stock analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 5.11% from the company’s previous close.
A number of other research analysts have also issued reports on REGN. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 5th. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Finally, Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective on the stock. in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $470.61.
Regeneron Pharmaceuticals (REGN) opened at 467.11 on Thursday. The stock has a 50 day moving average price of $499.60 and a 200-day moving average price of $421.63. The stock has a market cap of $49.31 billion, a PE ratio of 56.54 and a beta of 1.66. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.17 by $1.00. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post $13.63 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “BMO Capital Markets Analysts Give Regeneron Pharmaceuticals, Inc. (REGN) a $491.00 Price Target” was first reported by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://rinconhillneighbors.org/2017/08/04/bmo-capital-markets-analysts-give-regeneron-pharmaceuticals-inc-regn-a-491-00-price-target.html.
In related news, major shareholder Sanofi purchased 136,050 shares of the firm’s stock in a transaction dated Friday, June 2nd. The stock was bought at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $6,755,700. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,396 shares of company stock valued at $28,484,734. 10.40% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Grandfield & Dodd LLC boosted its position in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares in the last quarter. National Pension Service boosted its position in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $323,000. Princeton Capital Management Inc. boosted its position in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares in the last quarter. 66.79% of the stock is owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.